Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes-Reference-Cited by-同舟云学术

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes

Published:2016-05 Issue:5 Volume:137 Page:1498-1505.e1
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Naik Swati,Nicholas Sarah K.,Martinez Caridad A.,Leen Ann M.,Hanley Patrick J.,Gottschalk Steven M.,Rooney Cliona M.,Hanson I. Celine,Krance Robert A.,Shpall Elizabeth J.,Cruz Conrad R.,Amrolia Persis,Lucchini Giovanna,Bunin Nancy,Heimall Jennifer,Klein Orly R.,Gennery Andrew R.,Slatter Mary A.,Vickers Mark A.,Orange Jordan S.,Heslop Helen E.,Bollard Catherine M.,Keller Michael D.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference37 articles.

1. Transplantation outcomes for severe combined immunodeficiency, 2000-2009;Pai;N Engl J Med,2014

2. Patients with primary immunodeficiencies in pediatric intensive care unit: outcomes and mortality-related risk factors;Odek;J Clin Immunol,2014

3. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes;Buckley;Immunol Res,2011

4. Management of multidrug-resistant viruses in the immunocompromised host;Sellar;Br J Haematol,2012

5. Stem cell transplantation for primary immune deficiency;Worth;Curr Opin Hematol,2013

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies;International Journal of Molecular Sciences;2024-07-26

2. Efficacy and safety of adoptive T‐cell therapy in treating cytomegalovirus infections post‐haematopoietic stem cell transplantation: A systematic review and meta‐analysis;Reviews in Medical Virology;2024-06-15

3. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment;Nature Communications;2024-04-18

4. Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children’s Oncology Group study;Blood Advances;2024-02-29

5. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation;Frontiers in Immunology;2024-01-11